Oxford’s malaria vaccine shows effective results against vector-borne disease | The Financial Express

Oxford’s malaria vaccine shows effective results against vector-borne disease

On Wednesday, data from a mid-stage study on more than 400 young children who received a fourth dose of the Oxford shot after the primary three-dose regimen was published in the Lancet journal.

Oxford’s malaria vaccine shows effective results against vector-borne disease
According to Oxford scientist Adrian Hill, Oxford’s vaccine, called R21/Matrix-M, is likely more effective than Mosquirix in preventing the disease. (File)

The makers of the malaria vaccine from Oxford University said on Wednesday that the vaccine can be a crucial player in the global effort to combat the deadly mosquito-borne disease.

After decades of work, the only approved malaria vaccine, Mosquirix, made by British drugmaker GSK (GSK.L), was recently endorsed by the World Health Organization (WHO).

According to Oxford scientist Adrian Hill, Oxford’s vaccine, called R21/Matrix-M, is likely more effective than Mosquirix in preventing the disease that kills about 600,000 people every year despite roughly $3 billion spent annually on insecticides, bednets and anti-malarial drugs, as per a report by news agency Reuters.

It also has a manufacturing advantage, he said as quoted by Reuters, citing a deal with Serum Institute of India to produce 200 million doses annually, starting 2023.

In contrast, GSK, reportedly, has committed to produce up to 15 million doses of Mosquirix every year through 2028, well under the roughly 100 million doses a year of the four-dose vaccine the WHO says is needed long-term to cover around 25 million children.

GSK has said it cannot make enough Mosquirix to meet the vast demand without more funds from international donors.

ALSO READ | India has taken various measures toward its goal of eradicating Malaria. Why does this preventable vector-borne disease still loom large?

On Wednesday, data from a mid-stage study on more than 400 young children who received a fourth dose of the Oxford shot after the primary three-dose regimen was published in the Lancet journal.

Vaccine effectiveness was 80% in the group that received a higher dose of the immune-boosting adjuvant component of the vaccine, and 70% in the lower-dose adjuvant group, at 12 months following the fourth dose. The doses were administered ahead of the peak malaria season in Burkina Faso.

The complicated structure and lifecycle of the malaria parasite has long stymied efforts to develop vaccines. GSK’s Mosquirix was conceived back in the 1980s, and paved the way for the Oxford team to create a more potent vaccine, Hill said as quoted by Reuters.

However, it is difficult to make direct comparisons between the two shots, given data from an ongoing larger phase III trial testing the Oxford shot involving 4,800 participants is still to come.

Meanwhile, late-stage trial data published last year showed that if Mosquirix was administered ahead of peak malaria season in high transmission areas, it was nearly 63% effective against clinical malaria.

Comparisons between the two vaccines at this stage must be tentative, given they have not yet been compared head-to-head in the same trial, said David Conway from the London School of Hygiene & Tropical Medicine.

ALSO READ | Covid patients at higher risk of psychiatric, neurological conditions after two years: Lancet study

However, these phase II data suggest the Oxford shot is a step forward from Mosquirix, improving efficacy and the retention of immunity, said Alister Craig from the Liverpool School of Tropical Medicine. Oxford expects to submit phase III data to the WHO imminently, hoping for a key endorsement next year.

(With inputs from Reuters)

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.